Auranofin induces lethal oxidative and endoplasmic reticulum stress and exerts potent preclinical activity against chronic lymphocytic leukemia

Cancer Research

Volumn 74, Issue 9, 2014, Pages 2520-2532

  Fiskus, Warren ^a   Saba, Nakhle ^c   Shen, Min ^d   Ghias, Mondana ^c   Liu, Jinyun ^b   Gupta, Soumyasri Das ^e   Chauhan, Lata ^e   Rao, Rekha ^e   Gunewardena, Sumedha ^e   Schorno, Kevin ^f   Austin, Christopher P ^d   Maddocks, Kami ^g   Byrd, John ^g   Melnick, Ari ^h   Huang, Peng ^b   Wiestner, Adrian ^c   Bhalla, Kapil N ^a  

^a HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

^e UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^f UNIVERSITY OF KANSAS   (United States)

^g OHIO STATE UNIVERSITY   (United States)

^h WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AURANOFIN; GLUTAMATE CYSTEINE LIGASE; HEME OXYGENASE 1; REACTIVE OXYGEN METABOLITE; THIOREDOXIN REDUCTASE;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER MODEL; CANCER SURVIVAL; CELL PROTECTION; CELLULAR STRESS RESPONSE; CHROMOSOME 11Q; CHROMOSOME 17P; CHROMOSOME DELETION; CHRONIC LYMPHATIC LEUKEMIA; DRUG EFFICACY; DRUG POTENTIATION; ENDOPLASMIC RETICULUM STRESS; ENZYME INHIBITION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIMARY CELL CULTURE; PRIORITY JOURNAL; STROMA CELL; TRANSGENIC MOUSE; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; AURANOFIN; CELL LINE, TUMOR; CELL SURVIVAL; DRUG SCREENING ASSAYS, ANTITUMOR; ENDOPLASMIC RETICULUM STRESS; HISTONE DEACETYLASES; HSP90 HEAT-SHOCK PROTEINS; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MICE; MICE, TRANSGENIC; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES; THIOREDOXIN REDUCTASE 1; TRANSCRIPTOME; ZAP-70 PROTEIN-TYROSINE KINASE;

EID: 84900019686     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-13-2033     Document Type: Article

References (48)

1. Zenz T, Mertens D, Kuppers R, Dohner H, Stilgenbauer S. From pathogenesis to treatment of chronic lymphocytic leukaemia. Nat Rev Cancer 2010;10:37-50
2. Gribben JG, O'Brien S. Update on therapy of chronic lymphocytic leukemia. J Clin Oncol 2011;29:544-50
3. Zenz T, Gribben JG, Hallek M, Dohner H, Keating MJ, Stilgenbauer S. Risk categories and refractory CLL in the era of chemoimmunotherapy. Blood 2012;119:4101-7
4. Weir SJ, DeGennaro LJ, Austin CP. Repurposing approved and abandoned drugs for the treatment and prevention of cancer through public-private partnership. Cancer Res 2012;72:1055-8
5. Chapman CM, Sun X, Roschewski M, Aue G, Farooqui M, Stennett L, et al. ON 01910.Na is selectively cytotoxic for chronic lymphocytic leukemia cells through a dual mechanism of action involving PI3K/AKT inhibition and induction of oxidative stress. Clin Cancer Res 2012;18:1979-91
6. Trachootham D, Zhang H, Zhang W, Feng L, Du M, Zhou Y, et al. Effective elimination of fludarabine-resistant CLL cells by PEITC through a redox-mediated mechanism. Blood 2008;112:1912-22
7. Zhou Y, Hileman EO, Plunkett W, Keating MJ, Huang P. Free radical stress in chronic lymphocytic leukemia cells and its role in cellular sensitivity to ROS-generating anticancer agents. Blood 2003;101: 4098-104 (Pubitemid 36857891)
8. Bindoli A, Fukuto JM, Forman HJ. Thiol chemistry in peroxidase catalysis and redox signaling. Antioxid Redox Signal 2008;10:1549-64 (Pubitemid 351931936)
9. Trachootham D, Alexandre J, Huang P. Targeting cancer cells byROSmediated mechanisms: a radical therapeutic approach? Nat Rev Drug Discov 2009;8:579-91
10. Malhotra D, Portales-Casamar E, Singh A, Srivastava S, Arenillas D, Happel C, et al. Global mapping of binding sites for Nrf2 identifies novel targets in cell survival response through ChIP-Seq profiling and network analysis. Nucleic Acids Res 2010;38:5718-34
11. Wu RP, Hayashi T, Cottam HB, Jin G, Yao S, Wu CC, et al. Nrf2 responses and the therapeutic selectivity of electrophilic compounds in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 2010; 107:7479-84
12. Avery S. Molecular targets of oxidative stress. Biochem J 2011;434: 201-10
13. Boyault C, Zhang Y, Fritah S, Caron C, Gilquin B, Kwon SH, et al. HDAC6 controls major cell response pathways to cytotoxic accumulation of protein aggregates. Genes Dev 2007;21:2172-81 (Pubitemid 47360839)
14. Matthias P, Yoshida M, Khochbin S. HDAC6 a new cellular stress surveillance factor. Cell Cycle 2008;7:7-10
15. Kawaguchi Y, Kovacs JJ, McLaurin A, Vance JM, Ito A, Yao TP. The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress. Cell 2003;115:727-38 (Pubitemid 38030301)
16. Rao R, Nalluri S, Kolhe R, Yang Y, Fiskus W, Chen J, et al. Treatment with panobinostat induces glucose-regulated protein 78 acetylation and endoplasmic reticulum stress in breast cancer cells. Mol Cancer Ther 2010;9:942-52
17. Yang Y, Rao R, Shen J, Tang Y, Fiskus W, Nechtman J, et al. Role of acetylation and extracellular location of heat shock protein 90alpha in tumor cell invasion. Cancer Res 2008;68:4833-42
18. Trepel J, Mollapour M, Giaccone G, Neckers L. Targeting the dynamic HSP90 complex in cancer. Nat Rev Cancer 2010;10:537-49
19. Moulick K, Ahn JH, Zong H, Rodina A, Cerchietti L, Gomes DaGama EM, et al. Affinity-based proteomics reveal cancer-specific networks coordinated by Hsp90. Nat Chem Biol 2011;7:818-26
20. Rao R, Fiskus W, Yang Y, Herger B, Joshi R, Fernandez P, et al. HDAC6 inhibition enhances 17-AAG-mediated abrogation of HSP90 Chaperone function in human leukemia cells. Blood 2008;112:1886-93
21. Castro JE, Prada CE, Loria O, Kamal A, Chen L, Burrows FJ, et al. ZAP- 70 is a novel conditional heat shock protein 90 (Hsp90) client: inhibition of Hsp90 leads to ZAP-70 degradation, apoptosis, and impaired signaling in chronic lymphocytic leukemia. Blood 2005;106:2506-12 (Pubitemid 41510826)
22. Tabas I, Ron D. Integrating the mechanisms of apoptosis induced by endoplasmic reticulum stress. Nat Cell Biol 2011;13:184-90
23. Walter P, Ron D. The unfolded protein response: from stress pathway to homeostatic regulation. Science 2011;334:1081-6
24. Lin JH, Li H, Yasumura D, Cohen HR, Zhang C, Panning B, et al. IRE1 signaling affects cell fate during the unfolded protein response. Science 2007;318:944-9 (Pubitemid 350098984)
25. Rao R, Nalluri S, Fiskus W, Savoie A, Buckley K, Ha K, et al. Role of CAAT/enhancer binding protein homologous protein in panobinostatmediated potentiation of bortezomib-induced lethal endoplasmic reticulum stress in mantle cell lymphoma cells. Clin Cancer Res 2010;16:4742-54
26. Burger JA, Ghia P, Rosenwald A, Caligaris-Cappio F. The microenvironment in mature B-cell malignancies: a target for new treatment strategies. Blood 2009;116:3367-75
27. Woyach JA, Johnson AJ, Byrd JC. The B-cell receptor signaling pathway as a therapeutic target in CLL. Blood 2012;120:1175-84
28. Wiestner A. Emerging role of kinase targeted strategies in chronic lymphocytic leukemia. Blood 2012;120:4684-91
29. Davids MS, Deng J, Wiestner A, Lannutti BJ, Wang L, Wu CJ, et al. Decreased mitochondrial apoptotic priming underlies stroma-mediated treatment resistance in chronic lymphocytic leukemia. Blood 2012;120:3501-9
30. Zhang W, Trachootham D, Liu J, Chen G, Pelicano H, Garcia-Prieto C, et al. Stromal control of cystine metabolism promotes cancer cell survival in chronic lymphocytic leukaemia. Nat Cell Biol 2012;14: 276-86
31. Gandin V, Fernandes AP, Rigobello MP, Dani B, Sorrentino F, Tisato F, et al. Cancer cell death induced by phosphine gold(I) compounds targeting thioredoxin reductase. Biochem Pharmacol 2010;79: 90-101
32. Kim HS, Zhang X, Choi YS. Activation and proliferation of follicular dendritic cell-like cells by activated T lymphocytes. J Immunol 1994; 153:2951-61 (Pubitemid 24292521)
33. Burger JA, Tsukada N, Burger M, Zvaifler NJ, Dell'Aquila M, Kipps TJ. Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor- 1. Blood 2000;96:2655-63
34. Bichi R, Shinton SA, Martin ES, Koval A, Calin GA, Cesari R, et al. Human chronic lymphocytic leukemia modeled in mouse by targeted TCL1 expression. Proc Natl Acad Sci U S A 2002;99:6955-60 (Pubitemid 34526239)
35. Johnson AJ, Lucas DM, Muthusamy N, Smith LL, Edwards RB, De Lay MD, et al. Characterization of the TCL-1 transgenic mouse as a preclinical drug development tool for human chronic lymphocytic leukemia. Blood 2006;108:1334-8 (Pubitemid 44232033)
36. Sivina M, Hartmann E, Vasyutina E, Boucas JM, Breuer A, KeatingMJ, et al. Stromal cells modulate TCL1 expression, interacting AP-1 components and TCL1-targeting micro-RNAs in chronic lymphocytic leukemia. Leukemia 2012;26:1812-20
37. Appleton SD, Chretien ML, McLaughlin BE, Vreman HJ, StevensonDK, Brien JF, et al. Selective inhibition of heme oxygenase, without inhibition of nitric oxide synthase or soluble guanylyl cyclase, by metalloporphyrins at low concentrations. Drug Metabol Disposit 1999;27: 1214-9 (Pubitemid 29463610)
38. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Reg 1984;22:27-55
39. Krejsa CM, Franklin CC, White CC, Ledbetter JA, Schieven GL, Kavanaugh TJ. Rapid activation of glutamate cysteine ligase following oxidative stress. J Biol Chem 2010;285:16116-24
40. Scarbrough PM, Mapuskar KA, Mattson DM, Gius D, Watson WH, Spitz DR. Simultaneous inhibition of glutathione- and thioredoxindependent metabolism is necessary to potentiate 17AAG-induced cancer cell killing via oxidative stress. Free Radic Biol Med 2012;52: 436-43
41. Akerfelt M, Morimoto RI, Sistonen L. Heat shock factors: integrators of cell stress, development and lifespan. Nat Rev Mol Cell Biol 2010;11: 545-55
42. Debnath A, Parsonage D, Andrade RM, He C, Cobo ER, Hirata K, et al. A high-throughput drug screen for Entamoeba histolytica identifies a new lead and target. Nat Med 2012;18:956-60
43. Biswas S, Zhao X, Mone AP, Mo X, Vargo M, Jarjoura D, et al. Arsenic trioxide and ascorbic acid demonstrate promising activity against primary human CLL cells in vitro. Leuk Res 2010;34:925-31
44. Ni Chonghaile T, Sarosiek KA, Vo TT, Ryan JA, Tammareddi A, Moore Vdel G, et al. Pretreatmentmitochondrial priming correlates with clinical response to cytotoxic chemotherapy. Science 2011;334:1129-33
45. Rushworth SA, MacEwan DJ. HO-1 underlies resistance of AML cells to TNF-induced apoptosis. Blood 2008;111:3793-801
46. Mandal PK, Schneider M, Kölle P, Kuhlencordt P, Förster H, Beck H, et al. Loss of thioredoxin reductase 1 renders tumors highly susceptible to pharmacologic glutathione deprivation. Cancer Res 2010;70: 9505-14
47. Fath MA, Ahmad IM, Smith CJ, Spence J, Spitz DR. Enhancement of carboplatin-mediated lung cancer cell killing by simultaneous disruption of glutathione and thioredoxin metabolism. Clin Cancer Res 2011;17:6206-17
48. Sobhakumari A, Love-Homan L, Fletcher EV, Martin SM, Parsons AD, Spitz DR, et al. Susceptibility of human head and neck cancer cells to combined inhibition of glutathione and thioredoxin metabolism. PLoS ONE 2012;7:e48175.